The CDC said the injection is one of the first new medications to ease symptoms in patients with a bout of dementia and Alzheimer’s disease.
“In addition to offering further options for people struggling with Alzheimer’s disease, the data suggest the low-dose administration, without other dementia-related care management, can help retain the most productive portion of caregivers’ lives,” said Sandra O. Rabern, director of the CDC Division of Diabetes Translation.
The CDC conducted a survey of older people and found that roughly 5.8 million people with Alzheimer’s and dementia received help from an unpaid caregiver in the last year. The survey found that with the new shot, some 2.1 million people would be eligible for it.
The CDC estimates the need for the shots will rise by a quarter within 15 years as the population ages.
The test also provides some relief to individuals who may have previously had to avoid caregiving as a result of the symptoms of Alzheimer’s. Also, according to the CDC, patients who use the shot could lower the cost of care for other family members.
“We must do all we can to advance new, better treatments to ease the burdens of people with dementia and their loved ones, and this is an important step,” said Amy Bushatz, president and CEO of Aging.org.
Read the full story at The New York Times.
Dr. Ondrejka of Ondrejka’s Alzheimer’s Research Institute lends a hand in Alzheimer’s disease
Next battlefield in Alzheimer’s research: how women are affected
PHOTOS: World Alzheimer’s Day 2019